Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Beyond the Rainbow: Advancing 2S/LGBTQ+ Health Equity at a Time of Political Volatility.

Two-Spirit, lesbian, gay, bisexual, transgender, queer and other sexual and gender minority (2S/LGBTQ+) populations continue to experience profound health disparities. In this article, we prioritize f…

Thérapies de Conversion
Kia, H., Robinson, M., Lee, E. O. J., Salway, T., & Ross, L. E. (2024). Beyond the Rainbow: Advancing 2S/LGBTQ+ Health Equity at a Time of Political Volatility.. Healthc Pap, 22(1), 9-25. https://doi.org/10.12927/hcpap.2024.27390

[Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases].

Objective To analyze the clinical efficacy of microwave ablation in the colorectal cancer with simultaneously multiple liver metastases that was initially evaluated as potentially resectable. Methods …

Thérapies de Conversion
Han, L., Wu, X. L., Guo, F., Xi, Y. N., Chang, X. Y., Zhang, C. Z., Zhang, J. F., & Ma, P. C. (2024). [Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases].. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 46(2), 161-168. https://doi.org/10.3881/j.issn.1000-503X.15900

Current controversies in glia-to-neuron conversion therapy in neurodegenerative diseases.

Thérapies de Conversion
Cao, P., Li, J., Liu, Z., & Liang, G. (2024). Current controversies in glia-to-neuron conversion therapy in neurodegenerative diseases.. Neural Regen Res, 19(4), 723-724. https://doi.org/10.4103/1673-5374.382251

Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.

Given the highly heterogeneous characteristics of advanced gastric cancer (GC), most patients must receive neoadjuvant therapy or conversion therapy consisting of chemotherapy to decrease tumor grade …

Thérapies de Conversion
Zhu, J., Wang, Y., Xu, B., Pu, W., He, P., Zhang, J., Wang, H., & Chen, H. (2024). Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.. Photodiagnosis Photodyn Ther, 46, 104038. https://doi.org/10.1016/j.pdpdt.2024.104038

Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.

BACKGROUND: Programmed cell death protein 1 (PD-1) or its ligand (PD-L1) monoclonal antibody combined with bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor) has been est…

Thérapies de Conversion
Liang, X., Jiang, Y., Yao, W., Deng, Y., Yang, S., & Liu, Q. (2024). Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.. Transl Cancer Res, 13(3), 1508-1518. https://doi.org/10.21037/tcr-23-1333

Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer.

Super-extended (D2plus) lymphadenectomy after chemotherapy has been reported in only a few studies. This retrospective study evaluates survival outcomes in a Western cohort of locally advanced or olig…

Thérapies de Conversion
Marrelli, D., Piccioni, S. A., Carbone, L., Petrioli, R., Costantini, M., Malagnino, V., Bagnacci, G., Rizzoli, G., Calomino, N., Piagnerelli, R., Mazzei, M. A., & Roviello, F. (2024). Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer.. Cancers (Basel), 16(7). https://doi.org/10.3390/cancers16071376

Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.

The high mortality rate in hepatocellular carcinoma (HCC) is partially due to the fact that a significant number of patients are diagnosed at an intermediate or advanced stage, with surgical treatment…

Thérapies de Conversion
Chen, Q. F., Chen, S., Chen, M., Lyu, N., & Zhao, M. (2024). Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.. J Clin Transl Hepatol, 12(3), 298-304. https://doi.org/10.14218/JCTH.2023.00403

Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.

Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first-line standard-of-care treatments for uHCC are systematic therapies. However, treatments th…

Thérapies de Conversion
Wu, J., Wu, J., Li, S., Luo, M., Zeng, Z., Li, Y., Fu, Y., Li, H., Liu, D., Ou, X., Lin, Z., Wei, S., & Yan, M. (2024). Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.. Biosci Trends, 18(1), 42-48. https://doi.org/10.5582/bst.2023.01326

Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.

Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been a…

Thérapies de Conversion
Chen, Y., Chen, H., Yu, R., Zeng, X., Tian, D., Pu, Q., & Liu, Y. (2024). Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.. Lung Cancer, 189, 107476. https://doi.org/10.1016/j.lungcan.2024.107476

Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.

BACKGROUND: Data on the long-term oncological outcomes of patients who undergo conversion surgery (CS) in gastric cancer (GC) patients with peritoneal metastasis (PM) are limited.METHODS: GC patients …

Thérapies de Conversion
Yang, Z., Lu, S., Shi, M., Yuan, H., Wang, Z., Ni, Z., He, C., Zheng, Y., Zhu, Z., Liu, W., Yao, X., Zhang, J., Li, C., Yan, M., Yan, C., & Zhu, Z. (2024). Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.. Gastric Cancer, 27(2), 387-399. https://doi.org/10.1007/s10120-023-01452-8

[Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].

OBJECTIVE: To evaluate the efficacy and safty of China-made flumatinib mesylate in the treatment of chronic myeloid leukemia in chronic phase (CML-CP).METHODS: 42 CML-CP patients treated with Chinese …

Thérapies de Conversion
Li, Y. Y., & Wang, C. L. (2024). [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 32(1), 14-19. https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.01.004

Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects.

Research has shown that locoregional and/or systemic treatments can reduce the tumor stage, enabling radical surgical resection in patients with initially unresectable hepatocellular carcinoma. This i…

Thérapies de Conversion
Ma, Y. N., Jiang, X., Liu, H., Song, P., & Tang, W. (2024). Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects.. Biosci Trends, 17(6), 415-426. https://doi.org/10.5582/bst.2023.01322